Clinical trials: Biological Therapy
Malignant Solid Tumor
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
This trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts…
- Trial name
- MegaMOST (NCT04116541)
- Testing
- HDM201, Ribociclib, Cabozantinib
- Where
- 13 sites in France
- Volunteers
- 455 people
- Sponsor
- Centre Leon Berard
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT07383441
- Testing
- Axitinib, Biospecimen Collection, Bone Scan
- Where
- 41 sites in United States
- Volunteers
- 718 people
- Sponsor
- SWOG Cancer Research Network
Crohn's Disease, Ulcerative Colitis
Disease Course in an IBD Cohort in the Era of Biological Treatment
The aim of the study is to do a 7-year follow-up of a consecutive inception cohort of 562 adults and children diagnosed and registered with inflammatory bowel disease in 2003-04 in order to evaluate the consequences of biological…
- Trial name
- NCT01468090
- Where
- 2 sites in Denmark
- Volunteers
- 192 people
- Sponsor
- Hvidovre University Hospital
Advanced / Metastatic Solid Tumors, Advanced Malignancy
Immunotherapy Master Trial for Advanced Cancers
Over the past decade, cancer immunotherapy has profoundly transformed oncology by harnessing the patient's immune system to target tumors.
- Trial name
- METAREM (NCT07431073)
- Testing
- METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each
- Where
- France
- Volunteers
- 275 people
- Sponsor
- UNICANCER
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Major Depressive Disorder
Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study
This is a validation study that will replicate a completed study designed to assess biomarkers of treatment response to standard antidepressant treatment.
- Trial name
- NCT04162522
- Testing
- Escitalopram, Brexpiprazole
- Where
- 6 sites in Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Behcet's Disease, Vasculitis
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
Behçet's disease (BD) is a systemic vasculitis of arterial and venous vessels of any size, involving young patients (from 15 to 45 years). BD significantly increases morbidity and mortality.
- Trial name
- ITAC (NCT03371095)
- Testing
- Infliximab, Cyclophosphamide
- Where
- 27 sites in France
- Volunteers
- 53 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs
This randomized, double-blind, placebo-controlled study will use Magnetic Resonance Imaging (MRI) to assess the efficacy of tocilizumab plus non-biological DMARD in patients with moderate to severe rheumatoid arthritis who have…
- Trial name
- NCT01034397
- Testing
- tocilizumab [RoActemra/Actemra], non-biological DMARDs
- Where
- 11 sites in Portugal
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
Spondylitis, Ankylosing
Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers
The aim of this trial is the caracterisation of a predicting algorithm of the answering response for patients with etanercept treatment in spondyloarthritis disease.
- Trial name
- PRESA (NCT03033095)
- Testing
- Etanercept ® 50 mg
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Grenoble
Rheumatoid Arthritis
Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis
This small study is to investigate the efficacy and safety of Acthar as an adjunct therapy in patients with active rheumatoid arthritis (RA) who have had an inadequate response to disease modifying antirheumatic drugs (DMARDs)…
- Trial name
- NCT02434757
- Testing
- H.P. Acthar Gel
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ronald J. Rapoport, MD
Chemical Injury, Chemicals; Intoxication
The Medical Management in Patients Exposed to Weapons of Mass Destruction
Observation study measuring medical response in contaminated environment.
- Conditions
- Chemical Injury, Chemicals; Intoxication, Acute Respiratory Distress Syndrome, Distress Respiratory Syndrome
- Trial name
- CBRNEObs (NCT05026645)
- Testing
- Clinical interventions performed in acute settings (contaminated environment), Protection (clinician and patient), Decontamination (clinician and patient)
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 1,000 people
- Sponsor
- St. Justine's Hospital
Advanced Hormone Receptor-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial
This clinical trial tests the feasibility and utility of a biology guided therapy recommendations report to aid in determining treatment of hormone receptor positive breast cancer that may have spread from where it first started…
- Conditions
- Advanced Hormone Receptor-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT07590583
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation or bone marrow transplantation may allow the…
- Trial name
- NCT00008203
- Testing
- aldesleukin, recombinant interferon gamma, carboplatin
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
This phase II trial tests how well biologically guided radiation therapy (BgRT) and stereotactic body radiation therapy (SBRT) with osimertinib works for the treatment of EGFR positive non-small cell lung carcinoma that has…
- Trial name
- NCT06014827
- Testing
- Biospecimen Collection, Computed Tomography, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Takayasu Arteritis
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches. Biologic therapies such as tumor necrosis factor inhibitors and tocilizumab are commonly used in patients with refractory or…
- Trial name
- NCT07491913
- Testing
- Tociliuzumab, Infliximab, Adalimumab
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Breast Neoplasms
Randomized Controlled Trial Comparing MBSR to SET in Breast Cancer Patients
This study will compare three standard treatment programs commonly offered to patients with breast cancer. The three programs being compared are 1) Mindfulness Meditation-Based Stress Reduction (MBSR), 2)Supportive- Expressive…
- Trial name
- NCT00390169
- Testing
- Mindfulness Meditation-Based Stress Reduction, Supportive-Expressive Group Therapy
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Canadian Breast Cancer Research Alliance
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00027937
- Testing
- aldesleukin, filgrastim, sargramostim
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Hodgkin Disease, Lymphoma, Non-Hodgkin
Tissue Collection for Studies of Lymph Cancer
Background: Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis
- Trial name
- NCT01676805
- Where
- 2 sites in United States, Jamaica
- Volunteers
- 1,295 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine
The purpose of this study is to show that ViscoGel® is safe when administrated alone and as an adjuvant together with Act-HIB® vaccine in healthy volunteers and to evaluate the quantitative and qualitative effect on the immune…
- Trial name
- VSG-2011-101 (NCT01578070)
- Testing
- 0.2μg Act-HIB®, ViscoGel® and 0.2μg Act-HIB®, ViscoGel® and 2μg Act-HIB®
- Where
- Sweden
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Viscogel AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.